# Pakistan Chemicals Export Opportunities (HS 28-38)

![Yugalinks](https://www.yugalinks.com/trade/yugalinks-logo-v3-dark-mode.webp)

> Yugalinks sector export playbook

Explore Pakistan HS 28-38 chemicals export opportunities, product portfolio, buyer markets, growth signals, and diversification opportunities.

## Overview

- Exporter: Pakistan (PAK)
- Sector: Chemicals
- HS chapters: HS 28-38
- Latest trade year: 2024
- Sector exports: $56.9M
- Products: 27
- Buyer markets: 29
- Average CAGR: +14.2%
- Global sector size: $506.7B

## Product portfolio

| Product | Global size | Your exports | Opportunity | CAGR | Markets | Share |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| HS 300490 - Medicaments: consisting of mixed or unmixed products n.e.s. in heading no. 3004, for therapeutic or prophylactic uses, packaged for retail sale | $307.2B | $4.8M | $116.0B | -0.1% | 22 | +0.0% |
| HS 382499 - Chemical products, mixtures and preparations: n.e.c. heading 3824 | $29.6B | $6.5M | $20.1B | -7.4% | 11 | +0.0% |
| HS 300439 - Medicaments: containing hormones (but not insulin), adrenal cortex hormones or antibiotics, for therapeutic or prophylactic uses, packaged for retail sale | $23.2B | $1.2M | $13.4B | +21.1% | 6 | +0.0% |
| HS 300212 - Blood, human or animal, antisera, other blood fractions and immunological products: antisera and other blood fractions | $24.0B | $108.2K | $12.2B | +17.2% | 4 | +0.0% |
| HS 330210 - Odoriferous substances and mixtures: of a kind used in the food or drink industries | $7.9B | $20.2K | $10.7B | +76.2% | 3 | +0.0% |
| HS 300220 - Vaccines: for human medicine | $8.7B | $238.9K | $9.2B | +19.1% | 2 | +0.0% |
| HS 382200 - Reagents: diagnostic or laboratory reagents on a backing and prepared diagnostic or laboratory reagents whether or not on a backing, other than those of heading no. 3002 or 3006: certified reference material | $18.7B | $15.9K | $8.3B | +4.1% | 5 | +0.0% |
| HS 330499 - Cosmetic and toilet preparations: n.e.c. in heading no. 3304, for the care of the skin (excluding medicaments, including sunscreen or sun tan preparations) | $18.2B | $1.8M | $8.0B | +17.5% | 4 | +0.0% |
| HS 382600 - Biodiesel and mixtures thereof: not containing or containing less than 70% by weight of petroleum oils or oils obtained from bituminous minerals | $8.0B | $11.0M | $6.2B | +104.2% | 2 | +0.2% |
| HS 293499 - Nucleic acids and their salts, other heterocyclic compounds, n.e.c. in heading number 2934 | $6.7B | $10.2K | $5.5B | +5.6% | 2 | +0.0% |
| HS 293399 - Heterocyclic compounds: n.e.c. in headings no. 2933 | $6.9B | $6.9K | $5.0B | +13.3% | 1 | +0.0% |
| HS 330300 - Perfumes and toilet waters | $8.5B | $322.5K | $5.0B | +26.5% | 3 | +0.0% |
| HS 300215 - Blood, human or animal, antisera, other blood fractions and immunological products: immunological products, put up in measured doses or in forms or packings for retail sale | $9.8B | $187.9 | $4.1B | -55.0% | 2 | +0.0% |
| HS 293359 - Heterocyclic compounds: containing a pyrimidine ring (whether or not hydrogenated) or piperazine ring in the structure, (other than malonylurea (barbituric acid) and its derivatives),and loprazolam, mecloqualone, methaqualone, zipeprol and salts thereof | $3.5B | $27.8K | $3.2B | +104.2% | 1 | +0.0% |
| HS 382319 - Industrial monocarboxylic fatty acids: acid oils from refining: (other than stearic acid, oleic acid or tall oil fatty acids) | $2.0B | $1.7M | $2.9B | +106.6% | 2 | +0.1% |
| HS 282590 - Inorganic bases, metal oxides, hydroxides and peroxides: n.e.s. in heading no. 2825 | $1.5B | $1.3K | $2.4B | +10.4% | 1 | +0.0% |
| HS 300390 - Medicaments: (not containing antibiotics, hormones, alkaloids or their derivatives), for therapeutic or prophylactic uses, (not packaged for retail sale) | $3.8B | $11.4K | $2.2B | -0.5% | 2 | +0.0% |
| HS 381512 - Catalysts, supported: reaction initiators, reaction accelerators and catalytic preparations, with precious metal or precious metal compounds as the active substance, n.e.c. or included | $3.1B | $1.4K | $2.1B | -4.6% | 1 | +0.0% |
| HS 300420 - Medicaments: containing antibiotics (other than penicillins, streptomycins or their derivatives), for therapeutic or prophylactic uses, packaged for retail sale | $3.8B | $38.4K | $2.0B | +21.0% | 1 | +0.0% |
| HS 293590 - Sulphonamides: n.e.c. in heading no. 2935 | $1.1B | $2.0K | $1.4B | +95.2% | 1 | +0.0% |
| HS 291736 - Acids: aromatic polycarboxylic acids: terephthalic acid and its salts | $1.6B | $259.2K | $1.4B | -1.1% | 1 | +0.0% |
| HS 340220 - Washing and cleaning preparations: surface-active, whether or not containing soap (excluding those of heading no. 3401), put up for retail sale | $1.2B | $1.0K | $1.4B | +9.8% | 1 | +0.0% |
| HS 321590 - Ink: writing, drawing and other inks, n.e.c. in heading no. 3215, whether or not concentrated or solid | $674.3M | $30.1K | $1.1B | +13.4% | 1 | +0.0% |
| HS 300290 - Toxins, cultures of micro-organisms (excluding yeasts) and similar products | $2.7B | $1.6 | $1.0B | -51.0% | 1 | +0.0% |
| HS 294190 - Antibiotics: n.e.c. in heading no. 2941 | $883.6M | $42.2K | $989.9M | +28.6% | 1 | +0.0% |
| HS 310210 - Fertilizers, mineral or chemical: nitrogenous, urea, whether or not in aqueous solution | $2.0B | $28.7M | $963.0M | +4.5% | 1 | +2.4% |
| HS 290220 - Cyclic hydrocarbons: benzene | $1.4B | $83.7 | $895.5M | +65.8% | 1 | +0.0% |

## Best markets

- USA, Puerto Rico and US Virgin Islands (USA): $48.9B calculated opportunity across 12 products.
- Switzerland, Liechtenstein (CHE): $36.6B calculated opportunity across 4 products.
- Germany (DEU): $24.8B calculated opportunity across 10 products.
- China (CHN): $18.5B calculated opportunity across 7 products.
- Belgium (BEL): $18.4B calculated opportunity across 3 products.
- Italy (ITA): $9.8B calculated opportunity across 2 products.
- Slovenia (SVN): $9.7B calculated opportunity across 1 products.
- United Kingdom (GBR): $9.2B calculated opportunity across 4 products.
- Mexico (MEX): $8.1B calculated opportunity across 4 products.
- Netherlands (NLD): $8.1B calculated opportunity across 2 products.
- Spain (ESP): $8.0B calculated opportunity across 3 products.
- Canada (CAN): $7.5B calculated opportunity across 4 products.

## Growth stars

- HS 382319: +106.6% average CAGR, $2.9B calculated opportunity.
- HS 293359: +104.2% average CAGR, $3.2B calculated opportunity.
- HS 382600: +104.2% average CAGR, $6.2B calculated opportunity.
- HS 293590: +95.2% average CAGR, $1.4B calculated opportunity.
- HS 330210: +76.2% average CAGR, $10.7B calculated opportunity.
- HS 290220: +65.8% average CAGR, $895.5M calculated opportunity.
- HS 294190: +28.6% average CAGR, $989.9M calculated opportunity.
- HS 330300: +26.5% average CAGR, $5.0B calculated opportunity.
- HS 300439: +21.1% average CAGR, $13.4B calculated opportunity.
- HS 300420: +21.0% average CAGR, $2.0B calculated opportunity.

## Diversification opportunities

- HS 300490: 22 buyer markets, $116.0B calculated opportunity.
- HS 382499: 11 buyer markets, $20.1B calculated opportunity.
- HS 300439: 6 buyer markets, $13.4B calculated opportunity.
- HS 382200: 5 buyer markets, $8.3B calculated opportunity.
- HS 300212: 4 buyer markets, $12.2B calculated opportunity.
- HS 330499: 4 buyer markets, $8.0B calculated opportunity.
- HS 330210: 3 buyer markets, $10.7B calculated opportunity.
- HS 330300: 3 buyer markets, $5.0B calculated opportunity.
- HS 300220: 2 buyer markets, $9.2B calculated opportunity.
- HS 382600: 2 buyer markets, $6.2B calculated opportunity.

## Method

Reported trade observations and calculated indicators are shown separately. Validate buyers, standards, logistics, pricing, and competition before acting. [Read the Yugalinks methodology](https://www.yugalinks.com/methodology).

## Data sources

- Primary trade series: OECD (2025), Balanced international merchandise trade statistics (BIMTS) - HS2017-6D, OECD Data Explorer (accessed on 2026-08-30). [OECD Data Explorer](https://data-explorer.oecd.org/) - [OECD Terms & Conditions](https://www.oecd.org/termsandconditions/)
- CEPII BACI bilateral trade flows (202601): [dataset page](https://www.cepii.fr/CEPII/en/bdd_modele/bdd_modele_item.asp?id=37) - [BACI documentation](https://www.cepii.fr/DATA_DOWNLOAD/baci/doc/baci_webpage.html) - [Etalab 2.0 Open Licence](https://www.etalab.gouv.fr/wp-content/uploads/2018/11/open-licence.pdf)

This page presents derived Yugalinks views of reported observations and calculated indicators.